Dianthus Therapeutics, Inc. /DE/ Depreciation and Amortization
Dianthus Therapeutics, Inc. /DE/ (DNTH) reported Depreciation and Amortization of $421.00 thousand for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-03.
Discontinued › Cash Flow › Operating Activities
us-gaap:DepreciationDepletionAndAmortization · last filed 2023-08-03
- Dianthus Therapeutics, Inc. /DE/ depreciation, depletion and amortization for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- Dianthus Therapeutics, Inc. /DE/ depreciation, depletion and amortization for the quarter ending 2023-03-31 was $421.00K, a 17.61% decline year-over-year.
- Dianthus Therapeutics, Inc. /DE/ depreciation, depletion and amortization for the quarter ending 2022-12-31 was $466.00K, a 12.90% decline year-over-year.
- Dianthus Therapeutics, Inc. /DE/ depreciation, depletion and amortization for the quarter ending 2022-09-30 was $471.00K, a 11.47% decline year-over-year.
- Dianthus Therapeutics, Inc. /DE/ depreciation, depletion and amortization for fiscal 2022 was $1.93M, a 4.70% decline from fiscal 2021.
- Dianthus Therapeutics, Inc. /DE/ depreciation, depletion and amortization for fiscal 2021 was $2.02M, a 2.12% increase from fiscal 2020.
- Dianthus Therapeutics, Inc. /DE/ depreciation, depletion and amortization for fiscal 2020 was $1.98M, a 7.33% increase from fiscal 2019.
- Dianthus Therapeutics, Inc. /DE/ depreciation, depletion and amortization for fiscal 2019 was $1.84M, a 110.63% increase from fiscal 2018.
| Period end | Depreciation, Depletion and Amortization 3 month | Depreciation, Depletion and Amortization 6 month | Depreciation, Depletion and Amortization 9 month | Depreciation, Depletion and Amortization 12 month |
|---|---|---|---|---|
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $421.00K 10-Q · filed 2023-08-03 | $887.00K derived: sum of 3 quarters · filed 2023-08-03 | $1.36M derived: sum of 4 quarters · filed 2023-08-03 |
| 2023-03-31 | $421.00K 10-Q · filed 2023-05-15 | $887.00K derived: sum of 2 quarters · filed 2023-05-15 | $1.36M derived: sum of 3 quarters · filed 2023-05-15 | $1.83M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-12-31 | $466.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $937.00K derived: sum of 2 quarters · filed 2023-03-23 | $1.41M derived: sum of 3 quarters · filed 2023-08-03 | $1.93M 10-K · filed 2023-03-23 |
| 2022-09-30 | $471.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $948.00K derived: sum of 2 quarters · filed 2023-08-03 | $1.46M 10-Q · filed 2022-11-03 | $1.99M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-06-30 | $477.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $988.00K 10-Q · filed 2023-08-03 | $1.52M derived: sum of 3 quarters · filed 2023-08-03 | $2.06M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $511.00K 10-Q · filed 2023-05-15 | $1.05M derived: sum of 2 quarters · filed 2023-05-15 | $1.58M derived: sum of 3 quarters · filed 2023-05-15 | $2.06M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $535.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $1.07M derived: sum of 2 quarters · filed 2023-03-23 | $1.55M derived: sum of 3 quarters · filed 2023-03-23 | $2.02M 10-K · filed 2023-03-23 |
| 2021-09-30 | $532.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $1.01M derived: sum of 2 quarters · filed 2022-11-03 | $1.49M 10-Q · filed 2022-11-03 | $1.98M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $479.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $953.00K 10-Q · filed 2022-08-04 | $1.45M derived: sum of 3 quarters · filed 2022-08-04 | $1.94M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $474.00K 10-Q · filed 2022-05-16 | $969.00K derived: sum of 2 quarters · filed 2022-05-16 | $1.46M derived: sum of 3 quarters · filed 2022-05-16 | $1.96M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $495.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $990.00K derived: sum of 2 quarters · filed 2022-03-08 | $1.49M derived: sum of 3 quarters · filed 2022-03-08 | $1.98M 10-K · filed 2022-03-08 |
| 2020-09-30 | $495.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $990.00K derived: sum of 2 quarters · filed 2021-11-04 | $1.48M 10-Q · filed 2021-11-04 | $1.97M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $495.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $988.00K 10-Q · filed 2021-08-05 | $1.47M derived: sum of 3 quarters · filed 2021-08-05 | $1.96M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $493.00K 10-Q · filed 2021-05-06 | $978.00K derived: sum of 2 quarters · filed 2021-05-06 | $1.46M derived: sum of 3 quarters · filed 2021-05-06 | $1.91M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $485.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-03 | $968.00K derived: sum of 2 quarters · filed 2021-03-03 | $1.42M derived: sum of 3 quarters · filed 2021-03-03 | $1.84M 10-K · filed 2021-03-03 |
| 2019-09-30 | $483.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $935.00K derived: sum of 2 quarters · filed 2020-11-05 | $1.36M 10-Q · filed 2020-11-05 | $1.72M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | $452.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $875.00K 10-Q · filed 2020-08-06 | $1.23M derived: sum of 3 quarters · filed 2020-08-06 | $1.44M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | $423.00K 10-Q · filed 2020-05-07 | $782.00K derived: sum of 2 quarters · filed 2020-05-07 | $991.00K derived: sum of 3 quarters · filed 2020-05-07 | $1.15M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $359.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-03 | $568.00K derived: sum of 2 quarters · filed 2020-03-03 | $728.00K derived: sum of 3 quarters · filed 2020-03-03 | $875.00K 10-K · filed 2020-03-03 |
| 2018-09-30 | $209.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | $369.00K derived: sum of 2 quarters · filed 2019-11-13 | $516.00K 10-Q · filed 2019-11-13 | $645.00K derived: sum of 4 quarters · filed 2020-03-03 |
| 2018-06-30 | $160.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $307.00K 10-Q · filed 2019-08-08 | $436.00K derived: sum of 3 quarters · filed 2020-03-03 | $554.00K derived: sum of 4 quarters · filed 2020-03-03 |
| 2018-03-31 | $147.00K 10-Q · filed 2019-05-09 | $276.00K derived: sum of 2 quarters · filed 2020-03-03 | $394.00K derived: sum of 3 quarters · filed 2020-03-03 | |
| 2017-12-31 | $129.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-03 | $247.00K derived: sum of 2 quarters · filed 2020-03-03 | $376.00K 10-K · filed 2020-03-03 | |
| 2017-09-30 | $118.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $247.00K 10-Q · filed 2018-11-08 | ||
| 2017-06-30 | $129.00K 10-Q · filed 2018-08-09 | |||
| 2016-12-31 | $6.00K 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |